A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 28 Feb 2018 Planned End Date changed from 10 Feb 2020 to 25 Nov 2019.
- 06 Feb 2018 Planned end date changed from 25 Nov 2019 to 10 Feb 2020.
- 09 Nov 2017 Planned End Date changed from 4 Apr 2020 to 25 Nov 2019.